Invest and Sell American Gene Technologies International Stock

Q: How to sell American Gene Technologies International stock?

If you hold private company shares of American Gene Technologies International - whether as an employee or an early investor - Forge can help you sell them. 1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have. 2. Indicate your interest to sell your American Gene Technologies International stock on our platform. 3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.

Enterprise Value

Access American Gene Technologies International’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like American Gene Technologies International.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Access Stock Price

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

David Pauza Ph.D

Chief Science Officer

Norman Rogers

Executive, Business Development

Jeffrey Galvin

Co-Founder, Chief Executive Officer & Board Member

Neil Lyons

Chief Financial Officer & Executive Vice President

Board Members

Julia Brown

Qi Tang

Jeffrey Galvin

Aaron Galvin

Tommy Thompson JD

American Gene Technologies International stock FAQs

Can you buy American Gene Technologies International stock?

As American Gene Technologies International is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private company like American Gene Technologies International, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not an accredited investor, discover how to begin the process to potentially qualify for new investment opportunities.

How to buy American Gene Technologies International stock?

To invest in a private company like American Gene Technologies International through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

Create a free account to access Forge’s marketplace.
Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.

Can you sell American Gene Technologies International stock?

Yes, you may be able to sell your American Gene Technologies International stock, subject to certain conditions. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company's interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.

How to sell American Gene Technologies International stock?

If you hold private company shares of - whether as an employee or an early investor - Forge can help you sell them.

Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
Indicate your interest to sell your American Gene Technologies International stock on our platform.
Work with your dedicated Private Market Specialist who'll help guide you through every step of the transaction.

Is American Gene Technologies International a public company?

No, American Gene Technologies International is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.

What is American Gene Technologies International’s stock price?

American Gene Technologies International is a privately held company and therefore does not have a public stock price. However, you may access American Gene Technologies International’s private market stock price with Forge Data.

What is American Gene Technologies International’s stock ticker symbol?

American Gene Technologies International does not have an official ticker symbol because this company is not currently publicly traded.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Genetic Engineering and Biotechnology News 12/04/2023

AGT Spins Out Addimmune, Focusing on Functional HIV Cure

American Gene Technologies (AGT) is spinning out a new company, Addimmune, to focus on developing a cure for HIV. Addimmune will continue AGT's work on AGT103-T, a gene and cell therapy that completed Phase I trials with positive safety results. The therapy is a single-dose treatment that delivers gene-therapy modified, HIV-specific CD4 T cells to people with HIV, with the aim of restoring natural immune control of the virus.

The Business Journals 08/10/2023

American Gene Technologies spinout Addimmune to go public through SPAC merger

The article discusses grocery delivery start-up, Instacart's valuation reaching $39 billion following its latest funding round of $265 million. This valuation is triple its previous one in 2020, indicating a surge in demand for its service amid the pandemic. The firm plans to use the funds for expanding its business.

WTOP 08/10/2023

Rockville company working on HIV cure will go public

American Gene Technologies International plans to make its Addimmune division a publicly traded company via a special purpose acquisition company (SPAC). Addimmune is developing a gene and cell therapy for HIV, and the SPAC spinoff could raise $500 million to fund larger clinical studies. The public offering is expected to be completed in early 2024.

Fierce Biotech 08/10/2023

American Gene Technologies thinks spin spin spin is how you win, as HIV unit heads to SPAC

American Gene Technologies (AGT) has signed a blank-check deal to spin off its HIV-focused subsidiary, Addimmune, to special purpose acquisition company 10X Capital Venture Acquisition Corp. III. The deal, which sees all non-HIV assets spun out into a separate entity retaining the AGT name, is expected to close in Q1 2024. The agreement represents a pre-money enterprise value of $500 million for Addimmune and offers $300 million tied to milestones.

American Gene Technologies International Stock

Register To Buy and Sell Shares